Cargando…

Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia

BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Lusheng, Song, Minkyo, Rabkin, Charles S., Chung, Yunro, Williams, Stacy, Torres, Javier, Corvalan, Alejandro H., Gonzalez, Robinson, Bellolio, Enrique, Shome, Mahasish, LaBaer, Joshua, Qiu, Ji, Camargo, M. Constanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610335/
https://www.ncbi.nlm.nih.gov/pubmed/36301365
http://dx.doi.org/10.1007/s00535-022-01933-0
_version_ 1784819243610537984
author Song, Lusheng
Song, Minkyo
Rabkin, Charles S.
Chung, Yunro
Williams, Stacy
Torres, Javier
Corvalan, Alejandro H.
Gonzalez, Robinson
Bellolio, Enrique
Shome, Mahasish
LaBaer, Joshua
Qiu, Ji
Camargo, M. Constanza
author_facet Song, Lusheng
Song, Minkyo
Rabkin, Charles S.
Chung, Yunro
Williams, Stacy
Torres, Javier
Corvalan, Alejandro H.
Gonzalez, Robinson
Bellolio, Enrique
Shome, Mahasish
LaBaer, Joshua
Qiu, Ji
Camargo, M. Constanza
author_sort Song, Lusheng
collection PubMed
description BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with ≥ 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). RESULTS: Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tipα [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tipα [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). CONCLUSIONS: Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-022-01933-0.
format Online
Article
Text
id pubmed-9610335
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-96103352022-10-28 Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia Song, Lusheng Song, Minkyo Rabkin, Charles S. Chung, Yunro Williams, Stacy Torres, Javier Corvalan, Alejandro H. Gonzalez, Robinson Bellolio, Enrique Shome, Mahasish LaBaer, Joshua Qiu, Ji Camargo, M. Constanza J Gastroenterol Original Article—Alimentary Tract BACKGROUND: Chronic Helicobacter pylori infection may induce gastric intestinal metaplasia (IM). We compared anti-H. pylori antibody profiles between IM cases and non-atrophic gastritis (NAG) controls. METHODS: We evaluated humoral responses to 1528 H. pylori proteins among a discovery set of 50 IM and 50 NAG using H. pylori protein arrays. Antibodies with ≥ 20% sensitivity at 90% specificity for either group were selected and further validated in an independent set of 100 IM and 100 NAG using odds ratios (OR). A validated multi-signature was evaluated using the area under the receiver operating characteristics curve (AUC) and net reclassification improvement (NRI). RESULTS: Sixty-two immunoglobulin (Ig) G and 11 IgA antibodies were detected in > 10%. Among them, 22 IgG and 6 IgA antibodies were different between IM and NAG in the discovery set. Validated antibodies included 11 IgG (anti-HP1177/Omp27/HopQ [OR = 8.1, p < 0.001], anti-HP0547/CagA [4.6, p < 0.001], anti-HP0596/Tipα [4.0, p = 0.002], anti-HP0103/TlpB [3.8, p = 0.001], anti-HP1125/PalA/Omp18 [3.1, p = 0.001], anti-HP0153/RecA [0.48, p = 0.03], anti-HP0385 [0.41, p = 0.006], anti-HP0243/TlpB [0.39, p = 0.016], anti-HP0371/FabE [0.37, p = 0.017], anti-HP0900/HypB/AccB [0.35, p = 0.048], and anti-HP0709 [0.30, p = 0.003]), and 2 IgA (anti-HP1125/PalA/Omp18 [2.7, p = 0.03] and anti-HP0596/Tipα [2.5, p = 0.027]). A model including all 11 IgG antibodies (AUC = 0.81) had better discriminated IM and NAG compared with an anti-CagA only (AUC = 0.77) model (NRI = 0.44; p = 0.001). CONCLUSIONS: Our study represents the most comprehensive assessment of anti-H. pylori antibody profiles in IM. The target antigens for these novel antibodies may act together with CagA in the progression to IM. Along with other biomarkers, specific H. pylori antibodies may identify IM patients, who would benefit from surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-022-01933-0. Springer Nature Singapore 2022-10-27 2023 /pmc/articles/PMC9610335/ /pubmed/36301365 http://dx.doi.org/10.1007/s00535-022-01933-0 Text en © Japanese Society of Gastroenterology 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article—Alimentary Tract
Song, Lusheng
Song, Minkyo
Rabkin, Charles S.
Chung, Yunro
Williams, Stacy
Torres, Javier
Corvalan, Alejandro H.
Gonzalez, Robinson
Bellolio, Enrique
Shome, Mahasish
LaBaer, Joshua
Qiu, Ji
Camargo, M. Constanza
Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title_full Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title_fullStr Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title_full_unstemmed Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title_short Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia
title_sort identification of anti-helicobacter pylori antibody signatures in gastric intestinal metaplasia
topic Original Article—Alimentary Tract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610335/
https://www.ncbi.nlm.nih.gov/pubmed/36301365
http://dx.doi.org/10.1007/s00535-022-01933-0
work_keys_str_mv AT songlusheng identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT songminkyo identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT rabkincharless identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT chungyunro identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT williamsstacy identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT torresjavier identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT corvalanalejandroh identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT gonzalezrobinson identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT bellolioenrique identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT shomemahasish identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT labaerjoshua identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT qiuji identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia
AT camargomconstanza identificationofantihelicobacterpyloriantibodysignaturesingastricintestinalmetaplasia